Burzykowski, Tomasz.
Tomasz Burzykowski
Burzykowski, Thomasz
VIAF ID: 69222140 (Personal)
Permalink: http://viaf.org/viaf/69222140
Preferred Forms
- 200 _ | ‡a Burzykowski ‡b Tomasz
- 100 1 _ ‡a Burzykowski, Thomasz
- 100 1 _ ‡a Burzykowski, Tomasz
-
-
-
-
- 100 1 _ ‡a Burzykowski, Tomasz
-
- 100 1 _ ‡a Burzykowski, Tomasz
- 100 1 _ ‡a Burzykowski, Tomasz
- 100 1 _ ‡a Burzykowski, Tomasz
-
-
- 100 0 _ ‡a Tomasz Burzykowski
4xx's: Alternate Name Forms (10)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Angielsko-polski słownik terminów biostatystyki klinicznej | |
The assessment of the usefulness of hemilaminectomy without fenestration in the treatment of thoracolumbar disc disease in chondrodystrophic dogs | |
Computational methods and stochastic models in proteomics | |
The evaluation of surrogate endpoints | |
Explanatory model analysis : explore, explain, and examine predictive models | |
Linear mixed-effects models using R : a step-by-step approach | |
Linear Models with Homogeneous Variance | |
Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial | |
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. | |
Markov-chain-based heteroscedastic regression model for the analysis of high-resolution enzymatically 18O-labeled mass spectra. | |
Metody obliczeniowe i modele stochastyczne w proteomice | |
A modeling approach to the analysis of nerve regenerative experiments. | |
A multivariate linear model for investigating the association between gene-module co-expression and a continuous covariate | |
A Multivariate Negative-Binomial Model with Random Effects for Differential Gene-Expression Analysis of Correlated mRNA Sequencing Data | |
Neoadjuvant as Future for Drug Development in Breast Cancer--Letter. | |
No association of leukemia inhibitory factor (LIF) DNA polymorphisms with multiple sclerosis | |
A nonhomogeneous hidden markov model for gene mapping based on next-generation sequencing data. | |
p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland | |
The performance of discriminant analysis for differentiating between genotoxic and non-genotoxic carcinogens | |
Performance of Gene Selection and Classification Methods in a Microarray Setting: A Simulation Study | |
PLS-SEM Mediation Analysis of Gene-Expression Data for the Evaluation of a Drug Effect | |
Precision medicine needs randomized clinical trials | |
Predicted and observed thyroid cancer incidence in Poland after year 1986 | |
Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer | |
Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer | |
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials | |
PRT Trial: Modeling Muscle Fiber Specific-Force | |
Pseudo-likelihood estimation for a marginal multivariate survival model | |
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance | |
Quasi-optymalny wybór zmiennych warstwujących w badaniach reprezentacyjnych na przykładzie rolnictwa | |
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results | |
Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. | |
Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results | |
A "Refined Hydrogen Rule" and a "Refined Hydrogen and Halogen Rule" for Organic Molecules | |
Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer | |
Reply to the Comment on: | |
Resampling Plans for Frailty Models | |
The retrospective study of 93 patients with transmigration of mandibular canine and a comparative analysis with a control group | |
Risk factors for bovine herpesvirus-1 seropositivity | |
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis | |
Sequential double cross-validation for assessment of added predictive ability in high-dimensional omic applications | |
SII Project: Modeling Gains in Mathematics Achievement-Scores | |
Simplified modeling strategies for surrogate validation with multivariate failure-time data | |
Simultaneous mapping of multiple gene loci with pooled segregants | |
Statistical analysis of data from single molecule experiment | |
Statistical interaction in the survival analysis of early breast cancer using registry data: role of breast conserving surgery and radiotherapy | |
Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial | |
Surrogate endpoints in advanced sarcoma trials: a meta-analysis | |
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients | |
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. | |
Testing for trends in dose-response microarray experiments: a comparison of several testing procedures, multiplicity and resampling-based inference | |
Titrating Theileria parva: single stocks against combination of stocks | |
Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers | |
Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database | |
Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics | |
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better? | |
The use of background signal in the transformation of cDNA-microarray measurements. | |
Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials | |
The use of the isotopic distribution as a complementary quality metric to assess tandem mass spectra results | |
Using a Poisson approximation to predict the isotopic distribution of sulphur-containing peptides in a peptide-centric proteomic approach | |
Using Linear Mixed Models for Normalization of cDNA Microarrays | |
Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. | |
Vegetables affect the expression of genes involved in carcinogenic and anticarcinogenic processes in the lungs of female C57BL/6 mice. | |
Visualizing the agreement of peptide assignments between different search engines | |
Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma |